Dr. Eric Chan is the current Interventional Cardiology Fellow at Stanford University Medical Center (2019 to 2020). Dr. Chan was born and raised in Hong Kong where he received his medical education in the Li Ka Shing Faculty of Medicine, University of Hong Kong. After graduating in 2009, he underwent training in Internal Medicine as well as Cardiology in Queen Mary Hospital.
He was initially trained in cardiovascular imaging including echocardiography for cardiac surgery and structural heart interventions. He then assumed a unique, hybrid role as an interventionist as well, taking part in coronary angioplasty as well as structural heart interventions. He is also fervently interested in CIED implantations including cardiac resynchronization therapy, subcutaneous ICD and leadless pacemakers.
As of 2020, Dr. Chan has performed the following cardiac procedures:
? Over 1000 cardiac catheterizations, intravascular imaging and percutaneous coronary interventions (PCI), with over 100 primary PCI for acute myocardial infarction, including patients on mechanical circulatory support (VA-ECMO or Impella)
? 200 structural heart interventions (includes transcatheter aortic, mitral, tricuspid and pulmonary valve replacements), percutaneous mitral valve repair, left atrial appendage occluder implantation, paravalvular leak closure, closure of patent foramen ovale (PFO) and atrial septal defects (ASD) etc
? Over 300 cardiac implantable electronic devices (CIED) implantations and replacements, including leadless pacemaker (Micra), cardiac resynchronization therapy (CRT), subcutaneous implantable cardioverter-defibrillator (SICD) and left bundle pacing.
? Over 300 transesophageal echocardiograms (TEE) and 3000 transthoracic echocardiograms, including TEE during structural heart interventions.
Apart from his clinical services, he is also involved in studies on coronary stenting and OCT conducted in the University of Hong Kong, as well as training of medical students such as echocardiography workshops. He is also the executive producer of Hong Kong Valve, a regionally renowned heart team conference. His vision is to improve the outcomes of patients with advanced heart failure through evolving transcatheter therapies.